Interactions médicamenteuses
Apraclonidine + Selegiline
Gravité: Majeure
Apraclonidine and Selegiline: major interaction.
Dernière mise à jour
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
Résumé
Apraclonidine is an alpha-2 agonist, and labeling advises against its use with MAO inhibitors because of a possible rise in blood pressure. The pharmacological basis is not fully clear, and exposure is low with ophthalmic use, but the labeling warning remains.
Ce que signifie cette interaction, en termes simples
Apraclonidine and Selegiline can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Apraclonidine belongs to Cardiovascular; Selegiline belongs to Central Nervous System.
Pourquoi elle survient
Mechanism is not established; possible altered catecholamine handling with MAO inhibition affecting blood pressure.
Conduite à tenir
Avoid the combination where possible and choose another ocular hypotensive agent. If apraclonidine is essential, monitor blood pressure closely.
Questions à poser à votre pharmacien
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour débloquer les conseils complets de prise en charge pour Apraclonidine et Selegiline, les notes complémentaires, le détail des données probantes et le vérificateur d'interactions pour une ordonnance complète.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Essayez Pro+ gratuitement pendant 14 jours sur le web. Sans carte.
Autres interactions de Selegiline
- Amitriptyline + Selegiline Contre-indiquée
- Amoxapine + Selegiline Contre-indiquée
- Atomoxetine + Selegiline Contre-indiquée
- Benzphetamine + Selegiline Contre-indiquée
- Brimonidine + Selegiline Contre-indiquée
- Buprenorphine long-acting + Selegiline Contre-indiquée
Autres interactions de Apraclonidine
- Apraclonidine + Isocarboxazid Contre-indiquée
- Apraclonidine + Linezolid Majeure
- Apraclonidine + Phenelzine Majeure
- Apraclonidine + Rasagiline Majeure
- Apraclonidine + Tranylcypromine Majeure
Questions fréquentes
Can I take Apraclonidine with Selegiline?
MediHelp rates the interaction as major. Apraclonidine and Selegiline can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Apraclonidine is an alpha-2 agonist, and labeling advises against its use with MAO inhibitors because of a possible rise in blood pressure. The pharmacological basis is not fully clear, and exposure is low with ophthalmic use, but the labeling warning remains.
How serious is the interaction between Apraclonidine and Selegiline?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination where possible and choose another ocular hypotensive agent. If apraclonidine is essential, monitor blood pressure closely.
What other medicines interact with Selegiline?
MediHelp also lists interactions of Selegiline with, for example, Amitriptyline, Amoxapine, Atomoxetine. The full list is on the Selegiline page.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.